Pre-treating placenta-derived human mesenchymal stem cells (FMhMSCs) with a hyaluronan mixed ester of butyric and retinoic acid (HBR) potentiates their reparative capacity in rodent hearts. Our aim was to test FMhMSCs in a large-animal model by employing a novel combination of in vivo and ex vivo analyses.
Introduction
Once a candidate stem cell type for cardiac regeneration has been successfully tested in rodents, the subsequent recommendable step, albeit sometimes neglected, before the experimental findings are translated into clinical medicine, is to validate the new therapy in large-animal model. This process implies scaling up cell delivery, which might prove difficult and reveal previous overestimations of the beneficial effects. In addition, large mammals allow much finer assessments of cardiac function with standard diagnostic imaging and therefore more reliable and clinically relevant estimations of the reparative capacity of stem cells.
We have previously tested, in a rat model of myocardial infarction (MI), the cardio-regenerative properties of human mesenchymal stem cells obtained from term placenta and pre-conditioned in vitro with a mixed ester of hyaluronan, butyric, and retinoic acid (HBR). 1 Placental stem cells are emerging as appealing candidates for regenerative therapy, 2, 3 in that they can be harvested in large quantities, stored at birth for later use, and easily expanded, and are characterized by prominent multi-potency and low immunogenicity. 3, 4 We found that, after direct intra-myocardial injection in the border zone, HBR-pre-conditioned mesenchymal cells differentiated as vascular and muscle tissue and caused a marked reduction in infarct size. 1 Also, stem cells not pre-treated with HBR, although unable to regenerate cardiac tissue directly, caused a significant, but more modest reduction in infarct size. The only assessment of cardiac function was based on ejection fraction; hence, we could not determine possible correlations between different histological patterns of tissue regeneration and contractile performance and metabolism at the sites of cell implantation. Given these premises, the aim of the present study was to test the effects of implantation of human placental stem cells in a large-animal model of myocardial infarction; a particular focus was put on regional function and metabolism, since cell therapy of myocardial infarction targets primarily certain regions of the heart. To pursue our objective, we used a combination of positron emission tomography (PET) and magnetic resonance imaging (MRI), which are the gold standard for in vivo quantitative assessment of, respectively, myocardial flow/metabolism and contractile performance in well-defined segments of the cardiac wall. 5, 6 Moreover, MRI allows an accurate determination of infarct size in the beating heart. 7, 8 In vivo data were then corroborated by proteomic and histological analysis. The availability of selective anti-human antibodies enabled us to identify implanted cells and track their differentiation in the host pig tissue.
Methods

Synthesis of HBR
The glycoconjugate HBR is an ester between the hydroxyl groups of hyaluronan and the carboxyl groups of butyric acid and retinoic acid. The procedure for HBR synthesis and characterization is presented in detail elsewhere (see Supplementary material online). 9 
Mesenchymal stem cell isolation and culture
Fetal membrane-derived human mesenchymal stem cells (FMhMSCs) were isolated as previously described. 1 FMhMSCs were cultured for 14 days without or with 1.5 mg/mL HBR in culture medium (HBR-FMhMSCs). 1 Our investigation conformed with the principles outlined in the Declaration of Helsinki. According to the policy approved by our local ethical committee at the S. Orsola-Malpighi Hospital of the University of Bologna, Italy, all tissue samples were obtained after informed consent. 
Myocardial infarction and stem cell transplantation
In vivo imaging
Four weeks after MI, cardiac MRI and PET were performed, and haemodynamic recordings taken to evaluate global and regional changes in myocardial contractility, perfusion, and viability. For non-invasive and invasive diagnostic assessments, the animals were sedated with a continuous infusion of midazolam (0.1 mg kg -1 h -1 intravenous), allowed to breath spontaneously and positioned lying on their right side with the heart at the isocentre of the gantry unit. It was previously shown that similar doses of midazolam have an irrelevant effect on global and regional cardiac function. 10 Regional LV myocardial perfusion and glucose uptake were measured by PET, whereas LV regional contractility and infarct scar size were assessed by MRI, according to previously standardized protocols. 6 For both imaging techniques, the heart was scanned along basal, middle and apical cross-sectional planes (see Supplementary material online).
MRI measurements
Cine-MRI images were acquired with a 1.5 T scanner (Signa Excite HD; GE Medical Systems, Waukesha, WI, USA), using a non-breath-hold ECGgated, steady-state free precession pulse sequence (fast imaging employing steady state acquisition). 11 Global (end-diastolic and end-systolic volumes, ejection fraction, and cardiac output) and regional (end-systolic wall thickening, LVWT; and maximal circumferential shortening, LVEcc max ) LV functional parameters were measured as previously described. 6, 12 To detect and quantify post-infarct myocardial fibrosis, gadoliniumdelayed contrast-enhanced (Gd-DE) images were acquired in two-dimensional segmented inversion recovery-prepared gradient echosequence, 10 min after administration of contrast agent Gd-DTPA (0.2 mmol/kg intravenous), in short-axis views. In house custom-designed software was used to distinguish the dense infarct core from the heterogeneous infarct periphery ('grey zone'), whose extension is a strong clinical predictor of lethal arrhythmias. 13, 14 The endocardial and epicardial borders were outlined on the delayed-enhancement short-axis slices, and then the infarction core and 'grey zone' were quantified as a percentage of the total myocardium.
PET measurements
After overnight fasting, the pigs were scanned in a two-ring positron tomograph ECAT HR Plus (Siemens; CTI, Knoxville, TN, USA NH 3. After correction for partial volume effect and recovery coefficient, the image data were computed in a 37 LV segment model using dedicated software (Munich Heart; NM Software, Munich, Germany).
Regional myocardial glucose uptake, an index of myocardial viability, was assessed by 18 F-deoxyglucose ( 18 F-FDG, 10 mCi intravenous bolus)
followed by an emission scan of 50 min, as previously described. 6 
MRI and PET data analysis
In order to generate complementary data from MRI and PET acquisitions, cardiac images were divided into basal, middle and apical cross-sectional slices, and each slice was divided into 12 segments. The infero-septal border of the infarct area, identified by delayed enhancement, was considered as the reference point, and the segments were counted anticlockwise starting from that point ( Figure 1 ). For the sham-operated animals, the reference point was taken as the inferior septum. The segmental data were used to generate 12-point curves corresponding to the following parameters: LV end-systolic wall thickness (LVWT), LV maximal cirumferential shortening (LVEcc max ), and 13 NH 3 and 18 F-FDG uptake. The first half of the curve (first six LV segments) was taken to be the area of interest, since it corresponded to the cell-injected myocardium, i.e. infarct and anterior border zone. Uptake of 13 NH 3 and 18 F-FDG was calculated in each segment compared with the segment having the highest value of uptake and expressed as the percentage of the maximal uptake. The area under the curve (AUC) of interest was calculated using the trapezoidal rule, as previously described in experimental 16 and clinical studies 17 ( Figure 1 ). Data were analysed in blinded fashion under the supervision of cardiologists expert in PET and MRI.
Haemodynamics
Haemodynamics was assessed in sedated animals 4 weeks after infarction or sham surgery. Arterial pressure was measured via a fluid filled catheter, while LV pressure, dP/dt max and dP/dt min were measured using a solidstate pressure gauge (Millar Instruments Inc., Houston TX, USA) inserted percutaneously through the femoral artery and advanced into the LV cavity under fluoroscopic guidance. 18 The animals were then killed as described in Supplementary material online.
Histological analysis
Serial sections of 4 mm thickness were used for histological and immunofluorescence analysis. Slices were stained with haematoxylin and eosin or Picro-Mallory trichrome to assess, respectively, tissue structure and extracellular fibrosis. FMhMSCs-derived cells were identified by immunofluorescence using an antibody directed against human mitochondria (anti-Mitochondria, 1:50 dilution, clone 113-1; Millipore, Temecula, CA, USA) 1 , and their lineage was determined by co-immunofluorescence identifying specific markers. Cardiac, endothelial, and myofibroblast lineage-committed human cells were detected, respectively, with primary monoclonal antibodies directed against human connexin 43 (Cx43, 1:50 dilution; Invitrogen Corporation, Camarillo, CA, USA), cardiac troponin I (Tn-cI, 1:250 dilution; Abcam, Cambridge, UK), Von Willebrand factor (vWF, 1:2000 dilution; DakoCytomation, Carpenteria, CA, USA), and a-smooth muscle actin (aSMA, 1:9000 dilution; Sigma-Aldrich, MO, USA), which is a reliable marker of myofibroblastic cells. 19 Endogenous stem cell recruitment was assessed using antibodies directed against Stro-1 (1:100 dilution; R&D Systems, Inc., Minneapolis, MN, USA) and c-kit (1:200 dilution; DakoCytomation, Carpenteria, CA, USA) antigens. Cycling cells were identified with an antibody against the nuclear transcription factor Ki-67 (1:200 dilution; Novocastra Laboratories Ltd, Newcastle, UK; see Supplementary material online).
Proteomic study
The proteomic profile of LV tissue (5 mg) collected from the infarct border zone was determined in the three infarct groups (PBS, n ¼ 3; FMhMSC, n ¼ 3; and HBR-FMhMSC, n ¼ 3). LV from control animals (n ¼ 3) was used as a normal control. The analysis was performed by a multidimensional protein identification technology (MudPIT) approach, as previously described by us and by others (see Supplementary material online). 
Results
Mortality rate and haemodynamics
The overall mortality rate after MI was of 37.5%. The main cause of death was untreatable ventricular arrhythmia following LAD ligation. At 4 weeks, there were no significant differences among groups for heart rate, mean aortic pressure, LV end-diastolic pressure, dP/dt max and dP/dt min (see Supplementary material online, Table S1 ).
Infarct size determined by MRI
LV total infarct scar size and infarct core zone were not significantly different between the FMhMSCs and PBS groups, but they were reduced by approximately 64 and 44.6%, respectively, in the HBR-FMhMSCs group compared with the other two groups (Figure 2A and B) . In contrast, the grey zone size was not significantly different among the three groups ( Figure 2C ). Representative LV Gd-DE MRI images in short-axis view are showed in Figure 2D .
LV contractile performance
As shown in Table S1 (see Supplementary material online), 4 weeks after MI the ejection fraction, LV volumes, and cardiac output did not change significantly compared with the control hearts. Nevertheless, the analysis of regional cardiac function revealed marked differences among groups. As shown in Figure 3A and C, LVWT in segments one to five was depressed in all infarcted groups compared with the sham-operated group; however, it recovered significantly better in segments two and three of the HBR-FMhMSCs group compared with the PBS and FMhMSCs groups. LVEcc max , the second index of regional contractile function, also indicated a better recovery in the HBR-FMhMSCs group, although the differences among groups were less pronounced. The overall function of the six LV segments of interest was quantified by AUC, which indeed showed a better recovery of both LVWT and LVEcc max in the HBR-FMhMSCs group compared with the other two infarcted groups ( Figure 3B and D) .
Regional LV perfusion and metabolism
PET-measured myocardial blood perfusion was significantly reduced in LV segments three to five of the FMhMSCs and PBS groups compared with control pigs ( Figure 4A ). In contrast, myocardial perfusion of segments three and four was higher in the HBR-FMhMSCs compared with the PBS and FMhMSCs groups. Consistently, the AUC confirmed that HBR-FMhMSCs was the only group in which the perfusion of the region of interest was significantly higher compared with the PBS group ( Figure 4C) . As shown in Figure 4D , no significant differences could be detected, when considering the single segments, between 18 F-FDG uptake in the FMhMSC or HBR-FMhMSC groups vs. the PBS group, and they were all lower than control values. However, when considering the AUC, 18 F-FDG uptake was significantly higher in the HBR-FMhMSC, but not in the FMhMSC group, compared with the PBS group ( Figure 4F) .
No significant differences were observed in myocardial perfusion and metabolic rate of glucose of LV remote regions for any experimental conditions.
Histological analysis
Haematoxylin and eosin tissue staining revealed the presence of a mild inflammatory infiltrate in the LV infarct and border zone with no differences among groups (data not shown). The amount of interstitial collagen in the LV infarct border zone was significantly reduced in the HBR-FMhMSCs group compared with the FMhMSCs and PBS groups ( Figure 2E and F ) , while no significant changes were observed in the FMhMSCs group compared with the PBS group. As shown in Figure 2G and H, the density of myocardial capillaries was significantly increased in the LV border zone of the HBR-FMhMSCs group compared with the other infarct groups, whereas angiogenesis was significantly increased in both the FMhMSC and the HBR-FMhMSCs group compared with the PBS group.
Immunofluorescence indicated that the number of human mitochondria-positive cells was significantly higher in the LV border zone of the HBR-FMhMSCs group compared with the other infarct groups ( Figure 5A and Supplementary material online, Figure S1A ). To better assess the fate of transplanted human stem cells, we sought specific lineage markers. Double immunofluorescence indicated that the number of human stem cell-derived vessels ( Figure 5B and Supplementary material online, Figure S1B ) and aSMA-positive cells in the LV border zone was significantly higher in the HBR-FMhMSCs group compared with the FMhMSCs group ( Figure 5C and Supplementary material online, Figure S1C ). In contrast, we could not detect human cells expressing the cardiomyocytespecific proteins troponin I ( Figure 5D ) and connexin 43, and no markers of endogenously recruited stem cells. A low expression of human Cx43 was expected in aSMA-positive cells 23 derived from transplanted cells, but it is likely that histological analysis was not sufficiently sensitive to detect such small amounts of protein, as previously shown by others. 24 Finally, no cells of human origin were detected in LV of the PBS group or in the remote zones (data not shown). No cells positive for c-kit, Stro-1, and Ki67 were detected in the infarct border zone of any of the groups.
Proteomic analysis
The hierarchical clustering analysis showed that, overall, the proteomic profile in the LV border zone of the HBR-FMhMSC hearts was
Cardiac transplant of placenta-derived stem cells Figure 6A ). In particular, the homology between the protein profile of HBR-FMhMSC hearts and that of normal tissue was 45%, while this homology was 30% for FMhMSC and only 25% for PBS hearts. In contrast, the LV remote zone of all infarcted groups showed a proteomic profile similar to normal. Figure 6B , C and D shows selected metabolic, contractile and pro-survival cardiac proteins that were found to be up-or downregulated in the LV border zone of the three infarcted groups compared with control hearts. In particular, cardiac troponin I, a positive modulator of myocardial contractile function, 25 and carnitine palmitoyltransferase I, the enzyme regulating myocardial mitochondrial fatty acid oxidation, 26 were significantly down-regulated in the PBS group compared with the two groups that received stem cells. Conversely, tenascin C, an extracellular matrix glycoprotein that accelerates adverse ventricular postinfarction remodelling in surviving myocardium, 27 and lumican, a small leucine-rich proteoglycan causing fibrillogenesis in end-stage heart failure, 28 were up-regulated in the PBS group compared with the other two infarcted groups. FMhMSC hearts showed a downregulation of NADH dehydrogenase and an up-regulation of lumican compared with HBR-FMhMSC hearts.
Discussion
The present study shows that placental mesenchymal stem cells pretreated with HBR display marked reparative capacity in a pig model of acute myocardial infarction. The beneficial effects of this stem cell type have been previously reported by us and by others in rat myocardial infarction 1, 3 and are now precisely characterized in a more clinically relevant animal model. Consistent with our previous findings, HBR pre-treatment was critically important to endow placental stem cells with curative potential; 1, 29, 30 HBR commits mesenchymal stem cells into cardiovascular cell lineages, enhances their secretion of the vasculogenic and pro-trophic factors vascular endothelial growth factor and hepatocyte growth factor (HGF), 1, 29 and increases their synthesis of the pro-survival mediators Akt and Pim-1, 29 all effects which might favour their survival, proliferation, and paracrine activity in infarcted hearts. 30 Other authors have successfully tested mesenchymal stem cells of various origins in infarcted rodents, pigs, and dogs. 31 -33 FMhMSCs, first tested by us in rats, 1 have been successfully tested also by others, 3 prompting an editorial on their interesting therapeutic potential. 34 They offer at least two advantages. First, they can be obtained in large amounts from abundant fetal tissue that is otherwise disposed of as biological waste. Second, and more important, it is known that placenta-derived mesenchymal cells do not induce allogeneic or xenogeneic lymphocyte proliferation and actively suppress lymphocyte responsiveness. 35 In fact, similar to rats, 1,3 the fully immunocompetent pigs used in the present study did not activate major immune responses after delivery of FMhMSCs. The absence of tissue rejection in two different animal species subjected to xenotransplantation strongly supports the potential use of FMhMSCs for safe allogeneic cell therapy in humans. The present findings provide novel information that could have not been obtained without our combined analysis at functional, metabolic, histological, and molecular levels. We established a rigorous and sensitive method, based on state-of-the-art diagnostic imaging, for fine evaluations of regional functional recovery after cell therapy. The size of infarcts induced in our pigs was purposely small to minimize the occurrence of fibrillation or other severe arrhythmias during surgical procedures and/or the acute post-surgical phase. Given the limited extent of cardiac damage, 4 weeks later the haemodynamics and classical parameters of global ventricular function, such as ejection fraction, ventricular volumes, and cardiac output, were not significantly altered compared with sham-operated animals, with no differences among infarcted groups. Our experimental model is consistent with the clinical condition of small myocardial infarction (less than 15%) with preserved global cardiac function, in which no significant correlation is found between infarct size and LV ejection fraction. 36 MRI delayed enhancement revealed that total infarct size and core were reduced by 64 and 44.6%, respectively, in hearts treated with HBR-FMhMSCs compared with control infarcts. In addition, MRI-aided analysis of cardiac regional function showed significantly improved systolic wall thickening and shortening in hearts treated with HBR-FMhMSCs, especially in those wall segments corresponding to the infarct border zone. PET imaging proved perfectly complementary, as it showed a good match between contractile function and myocardial perfusion in the same ventricular segments. The overall 18 F-FDG uptake of the area of interest was also significantly higher in HBR-FMhMSCs-treated relative to untreated infarcts, although this metabolic index revealed less pronounced differences when single segments were compared. Taken together, the information obtained from in vivo imaging clearly indicated that delivery of FMhMSCs did not affect the post-infarction outcome, while a significant reduction in infarct size and recovery of cardiac function, perfusion and metabolism was found in animals receiving HBR-FMhMSCs. Again, such quantifiable differences among groups could have not been detected and in vivo findings not correctly interpreted without the 'magnifying glass' of MRI/PET assessment of selected cardiac regions.
Histological and proteomic analysis confirmed, in vitro, the reliability of in vivo cardiac imaging, while, in turn, the in vivo cardiac imaging oriented the pathophysiological interpretation of histological changes. As expected, the infarct border zone contained less fibrous tissue in hearts that received HBR-FMhMSCs compared with the other two infarcted groups. This seems inconsistent with the absence of significant changes in the grey zone size as detected by MRI. It should be noted, however, that the grey zone corresponds to a very heterogeneous tissue bordering the infarct periphery and is characterized by a mixture of normal and fibrotic myocardium. MRI can provide an estimate of the extension of this area, but cannot be as detailed as the histological analysis in the quantification of fibrotic vs. myocardial tissue. In contrast, albeit more pronounced in hearts injected with HBR-FMhMSCs, microvessel density was higher in both groups of treated hearts compared with control infarcts. In this case, the in vivo analysis proved necessary to avoid misinterpretations based on histology. In fact, despite significant vascular regeneration, border zone blood perfusion in hearts injected with FMhMSCs did not recover compared with control infarcts. Interestingly, the transplanted human stem cells seemed to differentiate only as endothelial and smooth muscle cells, thus directly contributing to vessel, but not to cardiomyocyte, regeneration. This finding is in contrast with our previous data in rats, 1 and supports the concept that, after cardiac delivery, stem cells take only little part in direct tissue regeneration, for instance by forming new vessels, while they might exert protective or pro-regenerative effects on surviving cardiomyocytes and other cell types by releasing paracrine factors. 29, 37 These include vascular endothelial growth factor, fibroblast growth factor-2, and HGF genes and enhanced secretion of their related products. It is conceivable that the pro-regenerative effects of conditioned stem cells are due to the enhancement of their paracrine activity, as suggested by our recent study in infarcted rat hearts injected with pure HBR. 29 Proteomic analysis is a formidable tool of investigation that, to date, has been little exploited for studies of cardiac cell therapy and might prove even more powerful if combined with in vivo imaging. 38 A clear advantage offered by overall protein expression profiling is the possibility to determine the phenotype of damaged and regenerating tissue, thus identifying differences that might suggest key molecular mechanisms involved in the reparative process, and to compare it with normal tissue in order to assess the biological effects of specific stem cell types. In the present study, proteomic analysis nicely corroborated in vivo findings, indicating a 45% homology between protein expressions in the border zone of hearts treated with HBR-FMhMSCs and normal tissue. Less homology was found in hearts receiving FMhMSCs, consistent with the smaller functional recovery favoured by those cells, despite their pro-angiogenic effect. Among the many alterations in protein expression that emerged from our analysis and that deserve future ad hoc studies, it is noteworthy that lumican, a member of the small leucine-rich proteoglycan family, was up-regulated in the border zone of hearts treated with FMhMSC, but not HBR-FMhMSC. Lumican contributes mainly to collagen fibre assembly and organization in fibrotic tissue of ischaemic myocardium and is localized in fibrotic tissue. 28, 39 Moreover, the reduced expression of critically important mitochondrial enzymes, such as NADH dehydrogenase and/or cytochrome complexes, points to an impaired metabolism in the border zone in the FMhMSCs and PBS groups, in accord with the reduced 18 F-FDG uptake assessed by PET. The fatty acid binding protein, necessary for the facilitated transport of fatty acid into cardiomyocytes, was also decreased; notoriously, fatty acids are the main cardiac energy substrate. 40 It is also interesting that carbonic anhydrase I, an intracellular pH sensor which plays an important role in the cardiac cell response to ischaemic acidosis, 41 was downregulated in hearts treated with FMhMSCs. Unfortunately, the 'omic' approach is not designed to test mechanisms; therefore, we do not know whether enzymatic changes were causally related to biochemical or to functional alterations, or both. In any case, they were not observed in infarcted hearts treated with HBR-FMhMSC, suggesting a better postinfarct recovery of the metabolic phenotype. An important limitation of our study is the use of small infarcts, with no changes in ejection fraction, to test the regional effects of stem cell therapy. This was very convenient to obtain a consistent experimental preparation and reduce pig mortality; however, further studies will be necessary to test whether HBR pre-treatment can potentiate mesenchymal stem cell therapy in a large-animal model of myocardial infarction with global depression of cardiac function.
In conclusion, our study defined, in a clinically relevant animal model, the beneficial effects of placental mesenchymal stem cells delivered to infarcted hearts and the need for their ex vivo preconditioning with molecules harbouring differentiating and paracrine 'logics' before transplantation. Our investigation provides new information generated by a novel multimodal in vivo and in vitro analysis. This dual imaging should be recommended at least for pilot assessments of cardiac therapy with new stem cell candidates, so as to avoid underestimations due to the use of indices such as ejection fraction and systemic haemodynamics, which may not be sufficiently sensitive.
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